Back to Top Skip to main content Skip to sub-navigation

DOD participates in new COVID-19 antibody combination prevention trial

Woman gets blood drawn Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | MHS Toolkits and Branding Guidance

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

COVID-19 Booster Shots

Infographic
8/27/2021
If you have an immune system that is moderately to severely compromised, the CDC recommends you may receive an additional dose of mRNA COVID-19 vaccine (Pfizer or Moderna). This would be at least 4 weeks after your second dose.

If you have an immune system that is moderately to severely compromised, the CDC recommends you may receive an additional dose of mRNA COVID-19 vaccine (Pfizer or Moderna). This would be at least 4 weeks after your second dose.

Recommended Content:

COVID-19 Vaccine Toolkit | Vaccine Eligibility | Coronavirus | COVID-19 Vaccine Efforts

Mask Guidance for Department of Defense Facilities

Infographic
7/30/2021
In accordance with CDC guidance, the Department of Defense (DOD) requires all Service members, Federal employees, onsite contractor employees, and visitors, regardless of vaccination status, to wear a mask in all indoor DOD facilities.   If you are not vaccinated, continue to physically distance consistent with applicable CDC and DOD Force Health Protection Guidance.

In accordance with CDC guidance, the Department of Defense (DOD) requires all Service members, Federal employees, onsite contractor employees, and visitors, regardless of vaccination status, to wear a mask in all indoor DOD facilities. If you are not vaccinated, continue to physically distance consistent with applicable CDC and DOD Force Health Protection Guidance.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

The Delta Variant: Are You Protected?

Infographic
6/28/2021
Graphic with the title, “Are you Protected?” and the TRICARE logo on the bottom right. States that the Delta variant of the virus is spreading and that the Pfizer and Moderna vaccines are effective. Links to www.tricare.mil/COVIDVaccine

Pfizer and Moderna vaccines are effective against the Delta Variant. If you've received your first dose, don't forget to get your second dose.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Delta Variant | Coronavirus | COVID-19 Vaccine Efforts

The Delta Variant

Infographic
6/28/2021
Graphic stating that the Delta variant is a reason to get vaccinated. The TRICARE logo is on the bottom right. Links to www.tricare.mil/COVIDVaccine

The Delta variant of the virus is a reason to get vaccinated. The variant is expanding, especially where vaccination rates are low.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Delta Variant | COVID-19 Vaccine Efforts | Coronavirus

The Delta Variant: Stop the Spread

Infographic
6/28/2021
Graphic describing the Delta variant. Includes three bullet points describing the variant and a link to www.tricare.mil/COVIDVaccine and includes the TRICARE logo on the bottom right.

The Delta variant is expanding, especially where vaccination rates are low. Visit www.tricare.mil/COVIDVaccine to learn more.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Delta Variant | Coronavirus | COVID-19 Vaccine Efforts

The Delta Variant: Fact Check

Infographic
6/28/2021
A Fact Check graphic. Features a quote in the center of the graphic and states that the Delta variant is a reason to get vaccinated. The TRICARE logo is on the bottom right. Links to www.tricare.mil/COVIDVaccine

The Delta variant of the virus is a reason to get vaccinated. This variant spreads easily, with increased rates of sickness and hospitalization.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Delta Variant | Coronavirus | COVID-19 Vaccine Efforts

COVID-19: Get Your Second Shot

Infographic
6/22/2021
Get Your Second Shot! You're not fully vaccinated - or protected - until you receive your second shot of the Pfizer or Moderna vaccine.

You're not fully vaccinated - or protected - until two weeks after getting your second shot of the Pfizer or Moderna vaccine.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts

How COVID-19 Vaccines Work

Infographic
6/9/2021
Describes how the mRNA and viral vector vaccines work to educate beneficiaries about the COVID-19 vaccines.

This graphic showing how the mRNA and viral vector vaccines work to educate beneficiaries about the COVID-19 vaccines. Graphics are informational and provide facts on how they work in our bodies.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Get to Know the COVID-19 Vaccines - Main Infographic

Infographic
6/9/2021
An infographic describing the COVID-19 Vaccines, How they Work and Safety Monitoring Processes

This infographic pulls all three COVID-19 topics together in one graphic: Getting to Know the COVID-19 Vaccines, How they Work and Safety Monitoring

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Get to Know the COVID-19 Vaccines

Infographic
6/9/2021
Assures beneficiaries that the COVID-19 vaccines will not give you the virus, does not affect our DNA, and is safe.

This graphic that assures beneficiaries that the vaccines will not give you the virus, does not affect our DNA, and is safe. Graphics include a person receiving the vaccine and a comparison graphic of COVID-19 trials versus other trials.

Recommended Content:

Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

COVID-19 Vaccines Safety Monitoring

Infographic
6/9/2021
Graphic that assures beneficiaries that the COVID-19 vaccines are monitored for safety. Has information on how they are being reviewed. Graphics include doctors in a laboratory and a doctor with a shield fending off the virus. The MHS and TRICARE logos are on the bottom right.

Graphic that assures beneficiaries that the COVID-19 vaccines are monitored for safety. Has information on how they are being reviewed. Graphics include doctors in a laboratory and a doctor with a shield fending off the virus.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

COVID-19 Vaccination Card Second Shot

Infographic
5/27/2021
Graphic saying that keeping track of your vaccination card is important. Includes a helpful tips section, a link to www.tricare.mil/covidvaccine, and what to do when you didn’t get your vaccination card or don’t have a copy. The TRICARE logo is on the bottom right of the page.

Keep track of your vaccination card. Tips include keeping your card on you and taking a picture of it as a backup copy.

Recommended Content:

COVID-19 Vaccine Toolkit | Costs and Documentation | Coronavirus

Is It Allergies or COVID-19?

Infographic
5/11/2021
Infographic that describes the difference between symptoms of allergies and those related to COVID-19

This Infographic provides a chart that outlines how to tell the difference between COVID-19 and allergy symptoms

Recommended Content:

Symptoms of COVID-19 | Coronavirus | COVID-19 Vaccine Toolkit

VAX Fact Breastfeeding

Infographic
4/19/2021
VAX Fact Q and A: Can I get the COVID-19 vaccine if I'm breastfeeding? It's up to you to decide.  The CDC says COVID-19 vaccines can be offered to pregnant or breastfeeding women.  If you have questions about getting vaccinated, a conversation with your healthcare provider may help but is not required.

An infographic answering the question of whether you can get the COVID-19 vaccine if you're breastfeeding.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

VAX Fact Protection Last

Infographic
4/19/2021
VAX Fact: How long does a COVID-19 vaccine protect me for? We do not know yet how long protection may last for those who receive a COVID-19 vaccine.  We do know a COVID-19 vaccine may reduce your chances of spreading the illness to others or facing more serious illness, including hospitalization. Getting a COVID-19 vaccine is a safer choice.

An infographic answering the question of how long the COVID-19 vaccine protection lasts.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts
<< < 1 2 3 4 > >> 
Showing results 1 - 15 Page 1 of 4

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.